2023
DOI: 10.1038/s41598-023-31392-3
|View full text |Cite
|
Sign up to set email alerts
|

A laser-induced mouse model of progressive retinal degeneration with central sparing displays features of parafoveal geographic atrophy

Abstract: There are no disease-modifying treatments available for geographic atrophy (GA), the advanced form of dry age-related macular degeneration. Current murine models fail to fully recapitulate the features of GA and thus hinder drug discovery. Here we describe a novel mouse model of retinal degeneration with hallmark features of GA. We used an 810 nm laser to create a retinal lesion with central sparing (RLCS), simulating parafoveal atrophy observed in patients with progressive GA. Laser-induced RLCS resulted in p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…61,62 Since then, it has been a popular damage model. Focal lesions in the retina have been conducted in a number of popular animal models including mouse 63,64 , macaque [65][66][67] and cats. 68,69 Laser damage is also clinically relevant as it is both experienced with accidental laser exposure 70,71 as well as purposeful ablation used in photocoagulation and as a therapy for retinal ischemic disease, retinopathy of prematurity 72 and diabetic retinopathy 73 .…”
Section: Focal Retinal Lesions For Tracking the Immune Responsementioning
confidence: 99%
“…61,62 Since then, it has been a popular damage model. Focal lesions in the retina have been conducted in a number of popular animal models including mouse 63,64 , macaque [65][66][67] and cats. 68,69 Laser damage is also clinically relevant as it is both experienced with accidental laser exposure 70,71 as well as purposeful ablation used in photocoagulation and as a therapy for retinal ischemic disease, retinopathy of prematurity 72 and diabetic retinopathy 73 .…”
Section: Focal Retinal Lesions For Tracking the Immune Responsementioning
confidence: 99%